跳到主要內容
Rallybid

已截止

全國感染和敗血症審計 – 急症NHS醫療機構

Healthcare Quality Improvement Partnership已就「全國感染和敗血症審計 – 急症NHS醫療機構」發布此招標,現已不再接受新的投標。

此招標已不再接受新的投標。 類似的進行中招標

用淺白語言說明,這項招標是什麼?

全國感染和敗血症審計 – 急症NHS醫療機構

這份合約旨在為英格蘭和威爾士的NHS醫院,進行一項關於嚴重感染和敗血症的全新全國臨床審計。目標是收集感染和敗血症護理的數據,以發現差異並隨著時間推動改進。審計將專注於護理的早期階段,這對於有效管理嚴重感染和迅速治療敗血症至關重要。

採購方有什麼要求?

  • 為英格蘭和威爾士的NHS資助護理提供為期三年的審計服務。
  • 提交的成本預算最高不得超過£1,146,300.00(不含增值稅)。
  • 確保投標金額不超過規定的預算上限。
  • 審計工作需與NHS England敗血症現代服務框架和威爾士NHS國家病人安全計劃等主要醫療倡議緊密配合。

這項招標適合哪些人?

此機會適合在臨床審計方面具有專業知識的機構,特別是那些與急症醫院環境中嚴重感染和敗血症管理相關的機構。

機器翻譯由 AI 翻譯,方便你閱讀。投標必須以採購方的語言(英文)撰寫。原文列於下方。 公告全文

同類招標的過往批出紀錄說明了甚麼?

  • 同類招標平均每項約有 2.4 份投標(19 項批出紀錄載有數目)。
  • 半數同類合約的批出金額介乎 £5,427,055 至 £14,496,441,中位數為 £11,155,000。

根據過去 36 個月 33 項批出紀錄:相同工種、相同地區、金額相近。可信程度:中。以上只反映過往情況,並非預測結果。 批出合約資料

誰贏得這項招標,金額是多少?

此招標尚未公布批出結果。

公告全文

原文(English)

National Infection and Sepsis Audit – Acute NHS settings

The contract for the Infection and Sepsis Audit - Acute care settings (NISA-Acute) will initially be delivered for NHS-funded care in England and Wales for a period of three years, at a maximum total budget of up to £ 1,146,300.00 excl VAT and £1,375,560.00 with VAT. Bids exceeding these limits will be rejected. All pricing submissions must be in regard to this 'core' value, and not inclusive of any extension costs or aspirational intent costs, i.e. Please only submit a cost schedule up to the maximum core value of £ 1,146,300.00 excl VAT and £1,375,560.00 with VAT. The maximum budget ‘core’ value excludes the potential two year extension and aspirational intent as described in section 14.3 of Annex A - Service Specification. Please note, there is no commitment by the Authority at this stage to include any of the below aspirational intent. Taking this aspirational intent into account, including the possibility that a contract extension may be offered for an additional 24 months, the potential ceiling value is £8,988,606.00 GBP including VAT. This is a new national clinical audit for severe infection and sepsis in acute NHS hospital settings. The aim is to provide benchmarked infection and sepsis care data to identify variation and drive improvement over time. Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. While it is an unusual complication of developing an infection, it can be triggered by any infection. When people die from an infection, it is most commonly due to sepsis. Sepsis is complex and hard to diagnose, with no single test and symptoms that overlap with other conditions (NHS England Modern Service Framework, 2026) Severe infections may lead to the development of sepsis, particularly in at-risk groups, and are one of the most common reasons for emergency admission to hospital. Both infection and sepsis are major causes of morbidity and mortality in the UK, and costly to the NHS and wider economy: In 2025 there were over 23,000 deaths involving sepsis (Office for National Statistics). Patients and carers who we engaged with as part of specification development told us of long-term impacts that some sepsis survivors experience, from reduced mobility and cognitive difficulties, to loss of limbs or vision impairments. Each year, the NHS in England spends over £1billion on sepsis care, and over £6.5billion on infection care. Wider economic costs are estimated at £10-15billion annually (York Health Economics Consortium, 2017). 1,300 clinical negligence claims were made regarding sepsis from 2020/21 to 2024/25, costing £65.3m in litigation. Most claims relate to delays and failures in treatment and diagnosis. Several major healthcare initiatives have been launched to help improve care related to sepsis and severe infection, including: NHS England’s sepsis Modern Service Framework (MSF), which aims to reduce death, life-threatening complications and long-term impact from sepsis and severe infection by at least 25% by 2035, as well as reducing health inequalities (published July 2026). NHS England’s National Improvement Programme for ‘Optimising the acute management of sepsis’ (as part of the MSF activities). The National Patient Safety Plan for NHS Wales 2026-2031, which includes sepsis care. The UK Anti-Microbial Resistance (AMR) National Action Plan, which pledges to strengthen infection prevention and control (IPC) and antimicrobial stewardship (AMS) in health and social care settings New NICE guidelines for recognition, diagnosis and early management of suspected sepsis, published in November 2025 (NG253-NG255) Establishing the NISA-Acute audit is a key ambition of the NHS England sepsis MSF, and the audit will be expected to align closely with all the initiatives listed above. The audit funders have selected ‘early stages of care’ as the initial priority for this audit because this is a critical point for effective severe infection management and the swift identification and treatment of sepsis. Prompt, effective treatment is vital to improving outcomes, and both Prevention of Future Death (PFD) reports and Health Services Safety Investigations Body (HSSIB) investigations have highlighted opportunities to improve care in this area.

文件

以電郵接收這些招標

每天一封電郵,列出你所選行業及地區的新招標。無需帳戶或密碼。

我們會先以電郵發送確認連結。在你使用連結之前,不會發送任何其他內容。 私隱聲明

快速解答

這項招標何時截止?

已於2026年10月27日截止。

這份合約價值多少?

採購方估計價值為£8,988,606。

採購方是誰?

採購方是Healthcare Quality Improvement Partnership。

同類招標通常有多少企業投標?

同類招標平均每項約有 2.4 份投標(19 項批出紀錄載有數目)。 根據過去 36 個月 33 項批出紀錄:相同工種、相同地區、金額相近。可信程度:中。以上只反映過往情況,並非預測結果。

類似的進行中招標